WVF Portfolio Company NanoBio Presents New Results Data at the National Foundation for Infectious Diseases

NanoBio, a biopharmaceutical company focused on the development and commercialization of vaccines and anti-infective treatments, and a Wolverine Venture Fund portfolio company, presented new data on its Herpes 2 (HSV-2) vaccine at this year’s National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (ACVR).  This is a great milestone for NanoBio–data from pre-clinical guinea pig studies demonstrated the ability of NanoBio’s intranasal NE vaccine to enhance protection against HSV-2 as compared to leading intramuscular vaccine candidates.

Looking ahead, the company plans to conduct additional studies in guinea pigs to optimize dosing and expects to advance into clinical testing in the near future.  Check out NanoBio’s news release to learn more about the results.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: